According to a new report, published by KBV research, The Global Bronchodilators Market size is expected to reach $27 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.
The Beta-Adrenergic market is exhibiting a CAGR of 3.6 % during the forecast period. This is because these drugs relax the muscles around the airways for dilating bronchial airways. The medication of this class is beta-2 agonist, which targets the smooth muscle cell receptors for airway dilation.
The Nasal (Inhalable) market is leading the segment in the Global Bronchodilators Market by Route of Administration in 2021; thereby, achieving a market value of $14.4 billion by 2028. The growth is attributed to the wide usage of the nasal as a route of administration for bronchodilators. This administration route is widely utilized as a metered-dose inhaler (MDI), dry powder inhaler, soft mist inhaler, and nebulizer.
The Chronic Obstructive Pulmonary Disease (COPD) market is showcasing a CAGR of 4.1% during (2022 - 2028). This results from the rising geriatric population, increasing the demand for COPD drugs. An individual with an age above 65 years is more exposed to COPD. Also, overdiagnosis is a factor that is associated with a high prevalence of COPD.
The North America market dominated the Global Bronchodilators Market by Region in 2021; thereby, achieving a market value of $12.4 billion by 2028. The Europe market is anticipated to grow at a CAGR of 4.4% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 4.6% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/bronchodilators-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Route of Administration
By Disease
By Geography
Companies Profiled
Unique Offerings 
